Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Thursday, 3 July 2014
- MRC Technology and AstraZeneca Renew Collaboration to Identify Novel Targets for Discovery Research Initiative brings together global expertise to share compound libraries and streamline drug discovery
- Thursday, 12 June 2014
- AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma Phase IIa clinical study to commence in patients with severe asthma
- Wednesday, 14 May 2014
- MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.